Cognitive-behavioral group treatment for driving-related anger, aggression, and risky driving in combat veterans: a pilot study.

The present study examined the preliminary effects of an 8-session group cognitive-behavioral treatment (CBT) designed to reduce driving-related anger, aggression, and risky driving behaviors in veterans. Participants (N = 9) with self-reported aggressive and risky driving problems completed self-report measures at pretreatment, posttreatment, and 1-month follow-up. Of those completing the treatment, 89% demonstrated reliable change in driving-related aggression and 67% evidenced reliable change in driving-related anger.

Psychosocial distress in young cancer survivors.

Objectives: To review existing literature about the psychosocial reactions of cancer patients and provide information about the needs of patients wishing to preserve fertility.

Data Sources: Journal articles, research studies.

Conclusion: The desire for biological parenthood is an important issue for cancer survivors.

Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

The anti-CD20 monoclonal antibody, rituximab, and interferon alpha (IFN) are active agents in advanced stage, indolent lymphoma. Some data obtained in vitro suggest upregulation of CD20 by IFN, and clinical trials have reported additive or synergistic activity of IFN with rituximab. A prospective phase II study in advanced stage, follicular and non-follicular indolent lymphoma was performed.